{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SARS-CoV-2+recombinant+protein+vaccine+Phase+2+Formulation+3",
    "query": {
      "intervention": "SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 3,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-01T21:52:50.441Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04969276",
      "title": "Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza Immunization",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Quadrivalent Inactivated Influenza High Dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "COVID-19 mRNA Vaccine (nucleoside modified)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 306,
      "start_date": "2021-07-16",
      "completion_date": "2022-02-08",
      "has_results": true,
      "last_update_posted_date": "2025-09-12",
      "last_synced_at": "2026-09-01T21:52:50.441Z",
      "location_count": 6,
      "location_summary": "Glendale, Arizona • San Diego, California • Vista, California + 3 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Vista",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04969276"
    },
    {
      "nct_id": "NCT04762680",
      "title": "Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3159,
      "start_date": "2021-02-24",
      "completion_date": "2023-06-29",
      "has_results": true,
      "last_update_posted_date": "2025-09-18",
      "last_synced_at": "2026-09-01T21:52:50.441Z",
      "location_count": 30,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 26 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04762680"
    },
    {
      "nct_id": "NCT04816669",
      "title": "A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "SARS-CoV-2 Infection",
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "BNT162b2",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "BioNTech SE",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 629,
      "start_date": "2021-04-01",
      "completion_date": "2021-12-02",
      "has_results": true,
      "last_update_posted_date": "2022-12-23",
      "last_synced_at": "2026-09-01T21:52:50.441Z",
      "location_count": 21,
      "location_summary": "Anaheim, California • Walnut Creek, California • Hialeah, Florida + 16 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04816669"
    }
  ]
}